Since constitutive STAT3 is often associated with TNBC and other aggressive breast cancer subtypes that currently lack effective therapies, using STAT5 to modulate STAT3 activity could be an interesting avenue to pursue. The gene discussed is STAT5B; the disease is breast carcinoma.